Iconic Therapeutics

company

About

Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells.

  • 11 - 50

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$4.11M
Industries
Biopharma,Biotechnology,Therapeutics
Founded date
Jan 1, 2002
Number Of Employee
11 - 50
Operating Status
Active

Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells. It is a biopharmaceutical company that has an exclusive license on issued Yale University patents for a novel recombinant protein called hI-con1. hI-con1 binds tissue factor (TF), triggering natural killer cells to selectively destroy pathologic neovascular blood vessels. Such cells include choroidal neovascularization (CNV) associated with wet age-related macular degeneration (wet AMD) and TF-expressing cancer cells and tumor-associated pathologic blood vessels (PBV). In addition to this cell-mediated cytotoxicity, hI-con1 may also interrupt the positive feedback loop between tissue factor and vascular endothelial growth factor (VEGF), thereby reducing VEGF levels. Phase 1 studies with hl-con1 are complete and no dose limited toxicities were observed. Evidence of dose-related biologic activity was observed.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$4.11M
Iconic Therapeutics has raised a total of $4.11M in funding over 2 rounds. Their latest funding was raised on Jun 15, 2018 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 15, 2018 Series Unknown $4.11M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
Iconic Therapeutics is funded by 2 investors. Diem Bioventures and Georgia Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Diem Bioventures Series Unknown
Georgia Venture Partners Series Unknown